Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8043833 Expression of soluble therapeutic proteins

Patent 8043833 was granted and assigned to Novo Nordisk on October, 2011 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Karl F. Johnson0

Aliakbar Mobasseri0

Bingyuan Wu0

Tarik Soliman0

Marc F. Schwartz0

Shawn A. DeFrees0

Date of Patent

October 25, 2011

0

Patent Application Number

120921250

Date Filed

September 6, 2006

0

Patent Citations Received

US Patent 11957735 Releasable GLP-1 conjugates

0

US Patent 11786599 Releasable conjugates

Patent Primary Examiner

Shulamith H. Shafer

0

Patent abstract

The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8043833 Expression of soluble therapeutic proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.